Genomic stratification of multiple myeloma treated with novel agents.

Abstract:

:Cytogenetic testing is now routinely performed for the prognostic work-up of multiple myeloma (MM). The abnormalities del(17p), t(4;14) and del(13q) have been established as predictors of poor outcome in patients with MM treated with conventional chemotherapy or stem cell transplant; chromosome 1q gains and 1p losses have also been identified as novel prognostic factors. In recent years, bortezomib and lenalidomide have emerged as effective treatments for both relapsed/refractory and newly diagnosed MM. However, the effect of cytogenetic abnormalities is unclear among patients with MM treated with these novel agents. Here we review recent studies that analyze the impact of specific genomic aberrations on the outcome of MM treated with bortezomib and/or lenalidomide.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Jiang A,Reece D,Chang H

doi

10.3109/10428194.2011.608449

subject

Has Abstract

pub_date

2012-02-01 00:00:00

pages

202-7

issue

2

eissn

1042-8194

issn

1029-2403

journal_volume

53

pub_type

杂志文章,评审
  • Involvement of HLA Antigens, Interleukin 2 Receptor and B-Cell Growth Factor in Interferon Action in Hairy Cell Leukemia.

    abstract::Little is known about the mechanism(s) by which alpha-interferon (aIFN), when used as a biotherapeutic agent, suppresses the malignant cells and restores the normal phenotype of cells in patients with hairy cell leukemia (HCL). In previous studies using scanning electron microscopy (SEM) we found that alFN induced uni...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009053529

    authors: Gamliel H,Gurfel D,Wu SH,Salzberg S,Golomb HM

    更新日期:1990-01-01 00:00:00

  • The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.

    abstract::From July 1983 to January 1991 a total of 622 patients were randomized (585 eligible) to compare the effects of hydroxyurea, interferon alpha (IFN), and busulfan on the duration of chronic phase, and survival. Further goals included the determination of prognostic parameters. 598 CML patients were documented and 575 e...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428199309047880

    authors: Hehlmann R,Heimpel H,Kolb HJ,Heinze B,Hochhaus A,Griesshammer M,Pralle H,Queisser WP,Essers U,Falge C

    更新日期:1993-01-01 00:00:00

  • Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.

    abstract::Chronic myeloid leukemia (CML) is a myeloproliferative disease well treated by tyrosine kinase inhibitors (TKIs). The aim was to identify genes with a predictive value for relapse-free survival after TKI cessation in CML patients. We performed whole-exome sequencing of DNA from six CML patients in long-lasting deep mo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1132420

    authors: Smirnikhina SA,Lavrov AV,Chelysheva EY,Adilgereeva EP,Shukhov OA,Turkina A,Kutsev SI

    更新日期:2016-07-01 00:00:00

  • Mantle cell lymphoma: state-of-the-art management and future perspective.

    abstract::Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. Most patients present with advanced stage disease, often with extranodal dissemination, and typically pursue an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190903288514

    authors: Weigert O,Unterhalt M,Hiddemann W,Dreyling M

    更新日期:2009-12-01 00:00:00

  • The Splenic White Pulp in Chronic Lymphocytic Leukaemia: A Microenvironment Associated with CR2 (CD21) Expression, Cell Transformation and Proliferation.

    abstract::Splenectomy specimens from 8 cases of chronic lymphocytic leukaemia (CLL) were examined. The infiltrate in the red pulp consisted predominantly of small lymphocytes. In contrast the predominant cells in the white pulp were pro-lymphocytes and para-immunoblasts. The Ki67 marker, which identifies cells in growth phase, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428199009169601

    authors: Lampert IA,Hegde U,Van Noorden S

    更新日期:1990-01-01 00:00:00

  • Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

    abstract::We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109067623

    authors: Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

    更新日期:1991-01-01 00:00:00

  • The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation.

    abstract::Gallium (67Ga) scan was performed in 29 CLL patients with chronic lymphocytic leukemia who were suspected on clinical grounds to have Richter's transformation (RT). Of 29 patients, nine had a positive 67Ga scan; seven of these had a subsequent biopsy that verified large-cell lymphoma or Hodgkin's disease. The other tw...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145959

    authors: Partyka S,O'Brien S,Podoloff D,Kantarjian H,Keating MJ

    更新日期:1999-12-01 00:00:00

  • Non-Hodgkin's lymphoma followed by plasmacytoma, both arising in A thyroid gland with Hashimoto's disease.

    abstract::We describe here a rare case of malignant lymphoma followed by plasmacytoma in Hashimoto's thyroiditis. The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428199909169627

    authors: Hasegawa Y,Itoh T,Tamagawa Y,Komeno T,Kojima H,Ninomiya H,Yatabe Y,Mori N,Nagasawa T

    更新日期:1999-11-01 00:00:00

  • CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.

    abstract::Platelet/endothelial cell adhesion molecule 1 (PECAM-1, CD31) is an immunoglobulin superfamily member expressed on the surface of platelets, leukocytes and endothelial cells. The role of CD31 in biology of lymphomas has not yet been systemically studied. Expression of cell surface CD31 was analyzed by flow cytometry o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1849678

    authors: Vockova P,Molinsky J,Klanova M,Karban J,Spacek M,Havranek O,Kupcova K,Kazantsev D,Trneny M,Klener P

    更新日期:2020-11-25 00:00:00

  • Comparison of the survivals between bone marrow transplantation and chemotherapy for acute leukemia in first remission--a Japanese single institution study.

    abstract::The outcome of sixty-four patients with acute leukemia in first remission who had been treated with either bone marrow transplantation (BMT) or conventional chemotherapy was retrospectively evaluated (a median follow-up of 37 months). Among them, 26 patients (age range; 14-42 years) received allogeneic BMT from HLA-id...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199209051015

    authors: Tamura S,Takemoto Y,Kanamaru A,Fujiwara H,Miyazaki E,Fujimori Y,Inoue N,Okamoto T,Kohsaki M,Kakishita E

    更新日期:1992-11-01 00:00:00

  • Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study.

    abstract::Contemporary intensive therapies are effective for the majority of pediatric T-lineage acute lymphoblastic leukemia (ALL) patients, thus current challenge is to identify patients who may benefit from alternative treatment modalities. Previously, we demonstrated that human leukemic cell growth in the severe combined im...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909058405

    authors: Uckun FM,Waurzyniak BJ,Sather HN,Sensel MG,Chelstrom L,Nachman J,Gaynon PS,Bostrom B,Ek O,Sarquis M,Steinherz PG,Reaman GH

    更新日期:1999-02-01 00:00:00

  • Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.

    abstract::We report the clinical features and outcome of 22 TLS-ERG+ leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260124

    authors: Pan J,Zhang Y,Zhao YL,Yang JF,Zhang JP,Liu HX,Wu T,Tong CR

    更新日期:2017-07-01 00:00:00

  • Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis.

    abstract::Obesity is a risk factor for mortality and relapse of certain cancers. However, existing evidence for pediatric leukemia is inconsistent. The aim of this systematic review and meta-analysis was to evaluate the association between obesity at diagnosis and pediatric acute leukemia mortality and relapse. This study syste...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析,评审

    doi:10.3109/10428194.2015.1076815

    authors: Amankwah EK,Saenz AM,Hale GA,Brown PA

    更新日期:2016-05-01 00:00:00

  • Case 36: a difficult diagnosis in a patient with fever and progressive multi-organ failure.

    abstract::A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701342703

    authors: Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

    更新日期:2007-07-01 00:00:00

  • Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

    abstract::PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patien...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.784969

    authors: Brander D,Rizzieri D,Gockerman J,Diehl L,Shea TC,Decastro C,Moore JO,Beaven A

    更新日期:2013-12-01 00:00:00

  • Drug development for recurrent and refractory classical Hodgkin lymphoma.

    abstract::Classical Hodgkin lymphoma (cHL) is highly treatable with chemotherapy alone or combined modality therapy. High dose therapy and autologous stem cell transplant is considered standard of care for patients who relapse. For patients who relapse following transplant or who are not candidates for high dose therapy, progno...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902756586

    authors: Wildes TM,Bartlett NL

    更新日期:2009-04-01 00:00:00

  • Tocilizumab, in search for a role in acute GVHD.

    abstract::Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...

    journal_title:Leukemia & lymphoma

    pub_type: 评论,杂志文章

    doi:10.1080/10428194.2019.1613545

    authors: Gergis U,van Besien K

    更新日期:2019-09-01 00:00:00

  • B cell chronic lymphocytic leukemia with florid reactive CD4+ T cell lymphocytosis in lymph nodes.

    abstract::This case is of an unusual florid reactive CD4+ T Cell lymphocytosis involving lymph node (LN) and overshadowing residual B chronic lymphocytic leukemia (CLL). A 65 year old female with a 9 year history of untreated B-CLL presented with weight loss, splenomegaly and lymphadenopathy. B-CLL was confirmed on the basis of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148519

    authors: Busmanis I,Hussein S,Feleppa F,Rockman S,Begley CG

    更新日期:1993-01-01 00:00:00

  • Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.

    abstract::We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809068569

    authors: Myers DE,Sicheneder A,Clementson D,Dvorak N,Venkatachalam T,Sev AR,Chandan-Langlie M,Uckun FM

    更新日期:1998-04-01 00:00:00

  • The role of radiation therapy in the management of primary central nervous system lymphoma.

    abstract::Primary central nervous system lymphoma (PCNSL) is an aggressive neoplasm with a poor prognosis. Early studies of whole brain radiation therapy (WBRT) alone revealed a robust initial response but high rates of local recurrence with long-term follow-up. The addition of high-dose methotrexate (HDMTX)-based chemotherapy ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2014.961014

    authors: Milgrom SA,Yahalom J

    更新日期:2015-05-01 00:00:00

  • The role of aberrant transcription factor in the progression of chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological and clinical features. The Philadelphia (Ph) chromosome and BCR/ABL fusion gene is the major cytogenetic and molecular marker of CML chronic phase. However, the molecular mechanisms of disease progression are not well known. R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802163305

    authors: Zhang S

    更新日期:2008-08-01 00:00:00

  • Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006411

    authors: Wang P,Pavletic ZS,Joshi SS

    更新日期:2002-09-01 00:00:00

  • Primary breast lymphoma: outcome of 7 patients and a review of the literature.

    abstract::Primary breast lymphomas (PBL) are uncommon neoplasms. Seven PBL were diagnosed between March 1993 and October 2002. A lumpectomy (n=4) or radical mastectomy (n=3) was performed; 5 patients were in clinical stage (CS) II and 2 in CS IV; 6 patients received the CEOP regimen (cyclophosphamide, vincristine, epirubicin an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190500126083

    authors: Vigliotti ML,Dell'olio M,La Sala A,Di Renzo N

    更新日期:2005-09-01 00:00:00

  • Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.

    abstract::Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.546016

    authors: Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

    更新日期:2011-04-01 00:00:00

  • Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.

    abstract::The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.603444

    authors: Markova J,Kahraman D,Kobe C,Skopalova M,Mocikova H,Klaskova K,Dedeckova K,Eich HT,Böll B,Dietlein M,Kozak T

    更新日期:2012-01-01 00:00:00

  • The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.

    abstract::INHBA (inhibin βA), a subunit of a ligand of the transforming growth factor-β superfamily, is known to play diverse roles in various solid tumors. However, its role in hematologic malignancies remains unexplored. Here, we investigated the function of INHBA in diffuse large B-cell lymphoma (DLBCL). Both mRNA and protei...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1372574

    authors: Jiang L,Si T,Yu M,Zeng X,Morse HC 3rd,Lu Y,Ouyang G,Zhou JX

    更新日期:2018-05-01 00:00:00

  • Leukoencephalopathy in childhood acute lymphoblastic leukemia with t(1;19).

    abstract::To clarify the incidence of leukoencephalopathy in patients with t(1;19) and their clinical characteristics, we studied 239 acute lymphoblastic leukemia (ALL) cases. The 1;19 translocation was found in 20 (8.5%) of the 239 children with ALL. Leukoencephalopathy occurred in 2 (10%) patients with t(1;19) during the earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909093734

    authors: Shikano T,Kobayashi R,Ishikawa Y

    更新日期:1999-03-01 00:00:00

  • MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.

    abstract::Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1272680

    authors: Guo Y,Strickland SA,Mohan S,Li S,Bosompem A,Vickers KC,Zhao S,Sheng Q,Kim AS

    更新日期:2017-09-01 00:00:00

  • Inhibition of GM-CSF production by recombinant human interleukin-4: negative regulator of hematopoiesis.

    abstract::Interleukin-4 (IL-4), also known as B-cell stimulatory factor-1 (BSF-1), was initially identified as a T-cell product that mediates anti-IgM-induced DNA synthesis in B-lymphocytes. Various aspects of this highly pleiotropic cytokine have been described, including those on hematopoietic progenitor cells. However, the r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509059661

    authors: Sawada K,Sato N,Koike T

    更新日期:1995-09-01 00:00:00

  • Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.

    abstract::In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1788015

    authors: Fox ML,García-Cadenas I,Pérez AM,Villacampa G,Piñana JL,Ortí G,Montoro J,Roldán E,Bosch Vilaseca A,Martino R,Salamero O,Saavedra S,Hernandez-Boluda JC,Esquirol A,Sierra J,Sanz J,Solano C,Bosch F,Barba P,Valcarcel D

    更新日期:2020-08-01 00:00:00